Financial Performance Summary - In 2025, the company achieved operating revenue of 525.57 million RMB, representing a year-on-year increase of 23.09% [2] - The net profit attributable to the parent company was 114.02 million RMB, showing a significant year-on-year growth of 122.01% [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 116.59 million RMB, with a year-on-year increase of 102.99% [2] - Total assets at the end of the reporting period reached 1,955.93 million RMB, up 11.35% year-on-year [2] - The equity attributable to the parent company was 1,492.15 million RMB, reflecting a year-on-year growth of 7.11% [2] Business Operations and Key Factors - The company's core business segment, DEL, maintained steady growth, contributing to overall profit enhancement due to high gross margins [3] - The UK subsidiary further solidified the development of the FBDD/SBDD platform, with milestone revenues achieved from client projects [3] - The OBT segment showed significant revenue growth through the commercialization of small nucleic acid projects, aided by the efficient operation of an automated high-throughput chemical synthesis platform [3] - The company reported a significant increase in operating profit of 125.67 million RMB, a year-on-year growth of 99.58% [5] - The total profit reached 125.91 million RMB, marking a year-on-year increase of 100.62% [5] Non-Operating Gains and Losses - The company experienced a decrease in fair value losses on financial liabilities, which positively impacted overall financial performance [4]